154 related articles for article (PubMed ID: 32731576)
1. Antinociceptive and Cytotoxic Activity of Opioid Peptides with Hydrazone and Hydrazide Moieties at the C-Terminus.
Dyniewicz J; Lipiński PFJ; Kosson P; Bochyńska-Czyż M; Matalińska J; Misicka A
Molecules; 2020 Jul; 25(15):. PubMed ID: 32731576
[TBL] [Abstract][Full Text] [Related]
2. Antinociceptive profile of potent opioid peptide AM94, a fluorinated analogue of biphalin with non-hydrazine linker.
Mollica A; Costante R; Stefanucci A; Pinnen F; Lucente G; Fidanza S; Pieretti S
J Pept Sci; 2013 Apr; 19(4):233-9. PubMed ID: 23136069
[TBL] [Abstract][Full Text] [Related]
3. In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity.
Matalińska J; Lipiński PFJ; Kosson P; Kosińska K; Misicka A
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086743
[TBL] [Abstract][Full Text] [Related]
4. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the interaction between the atypical agonist c[YpwFG] and MOR.
Gentilucci L; Squassabia F; De Marco R; Artali R; Cardillo G; Tolomelli A; Spampinato S; Bedini A
FEBS J; 2008 May; 275(9):2315-37. PubMed ID: 18397320
[TBL] [Abstract][Full Text] [Related]
6. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
[TBL] [Abstract][Full Text] [Related]
7. Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic.
Piekielna J; De Marco R; Gentilucci L; Cerlesi MC; Calo' G; Tömböly C; Artali R; Janecka A
Biopolymers; 2016 May; 106(3):309-17. PubMed ID: 27038094
[TBL] [Abstract][Full Text] [Related]
8. Design of Analgesic Trivalent Peptides with Low Withdrawal Symptoms: Probing the Antinociceptive Profile of Novel Linear and Cyclic Peptides as Opioid Pan Ligands.
Stefanucci A; Minosi P; Pieretti S; Tanguturi P; Molnar G; Scioli G; Marinaccio L; Della Valle A; Streicher JM; Mollica A
ACS Chem Neurosci; 2023 Feb; 14(3):506-515. PubMed ID: 36651179
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ
J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170
[TBL] [Abstract][Full Text] [Related]
10. Highly potent side chain-main chain cyclized dermorphin-deltorphin analogues: an integrated approach including synthesis, bioassays, NMR spectroscopy and molecular modelling.
Ro S; Zhu Q; Lee CW; Goodman M; Darlak K; Spatola AF; Chung NN; Schiller PW; Malmberg AB; Yaksh TL
J Pept Sci; 1995; 1(3):157-74. PubMed ID: 9222993
[TBL] [Abstract][Full Text] [Related]
11. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW
Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.
Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M
J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268
[TBL] [Abstract][Full Text] [Related]
13. Cyclic mu-opioid receptor ligands containing multiple N-methylated amino acid residues.
Adamska-Bartłomiejczyk A; Janecka A; Szabó MR; Cerlesi MC; Calo G; Kluczyk A; Tömböly C; Borics A
Bioorg Med Chem Lett; 2017 Apr; 27(8):1644-1648. PubMed ID: 28318942
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of dermorphin analogues containing N-substituted amino acids in the 2-position of the peptide sequence.
Schmidt R; Kálmán A; Chung NN; Lemieux C; Horváth C; Schiller PW
Int J Pept Protein Res; 1995 Jul; 46(1):47-55. PubMed ID: 7558596
[TBL] [Abstract][Full Text] [Related]
15. The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Yamamoto T; Nair P; Jacobsen NE; Davis P; Ma SW; Navratilova E; Moye S; Lai J; Yamamura HI; Vanderah TW; Porreca F; Hruby VJ
J Med Chem; 2008 Oct; 51(20):6334-47. PubMed ID: 18821747
[TBL] [Abstract][Full Text] [Related]
16. The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment.
Pasquinucci L; Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Ronsisvalle G
Life Sci; 2012 Jan; 90(1-2):66-70. PubMed ID: 22100511
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand.
Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L
Life Sci; 2012 Jun; 90(25-26):957-61. PubMed ID: 22580287
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potentially biased agonists of mu-opioid receptor (MOR) through molecular docking, pharmacophore modeling, and MD simulation.
Jiang X; Li S; Zhang H; Wang LL
Comput Biol Chem; 2021 Feb; 90():107405. PubMed ID: 33184004
[TBL] [Abstract][Full Text] [Related]
19. Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.
Spetea M; Greiner E; Aceto MD; Harris LS; Coop A; Schmidhammer H
J Med Chem; 2005 Jul; 48(15):5052-5. PubMed ID: 16033285
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.
Yamamoto T; Nair P; Davis P; Ma SW; Navratilova E; Moye S; Tumati S; Lai J; Vanderah TW; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 2007 Jun; 50(12):2779-86. PubMed ID: 17516639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
